Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Abintus Bio Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split across 2 distinct examiners and 2 distinct art units, indicating a wider technical footprint than a single-application portfolio. This distribution suggests that the company is pursuing multiple innovations that fall under different classification codes within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for this portfolio is JACKSON III, WALTER, who is managing 1 pending. This means that the 2 pending office actions are shared between 2 distinct examiners, requiring the applicant to manage different sets of examination styles and technical perspectives simultaneously. This diversity in examiners can lead to different prosecution timelines for the various applications in the portfolio.
The involvement of 2 distinct art units implies that the portfolio is being evaluated against different sets of prior art. With 2 pending office actions, the company must coordinate its prosecution strategy to ensure consistency across its filings. Practitioners should monitor the progress of both matters to identify any overlapping technical issues that might arise during the examination process with JACKSON III, WALTER and the other assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924080 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | JACKSON III, WALTER | — |
| 17419239 | CAR T CELL METHODS AND CONSTRUCTS | KIM, TAEYOON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17419239 | CAR T CELL METHODS AND CONSTRUCTS | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17924080 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | JACKSON III, WALTER | 1674 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17419239 | CAR T CELL METHODS AND CONSTRUCTS | KIM, TAEYOON | 1631 | §103§112 | Final Rejection | — | Pending | Jun 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbintus Bio Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Walter Jackson III has the most, with 1 of Abintus Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
